Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Severe hypoglycemia is a feared complication of type 1 diabetes; yet, few trials have targeted prevention using optimized self-management (educational, therapeutic, and technological support). We aimed to investigate whether improved awareness and reduced severe hypoglycemia, achieved during an intensive randomized clinical trial (RCT), were sustained after return to routine care. RESEARCH DESIGN AND METHODS: Ninety-six adults with type 1 diabetes (29 ± 12 years’ duration) and impaired awareness of hypoglycemia at five U.K. tertiary referral diabetes centers were recruited into a 24-week 2 × 2 factorial RCT (HypoCOMPaSS). Participants were randomized to pump (continuous subcutaneous insulin infusion [CSII]) or multiple daily injections (MDIs) and real-time continuous glucose monitoring (RT-CGM) or self-monitoring of blood glucose (SMBG), with equal education/attention to all groups. At 24 weeks, participants returned to routine care with follow-up until 24 months, including free choice of MDI/CSII; RT-CGM vs. SMBG comparison continued to 24 months. Primary outcome was mean difference (baseline to 24 months [between groups]) in hypoglycemia awareness. RESULTS: Improvement in hypoglycemia awareness was sustained (Gold score at baseline 5.1 ± 1.1 vs. 24 months 3.7 ± 1.9; P < 0.0001). Severe hypoglycemia rate was reduced from 8.9 ± 12.8 episodes/person-year over the 12 months prestudy to 0.4 ± 0.8 over 24 months (P < 0.0001). HbA1c improved (baseline 8.2 ± 3.2% [66 ± 12 mmol/mol] vs. 24 months 7.7 ± 3.1% [61 ± 10 mmol/mol]; P = 0.003). Improvement in treatment satisfaction and reduced fear of hypoglycemia were sustained. There were no significant differences between interventions at 24 months. CONCLUSIONS: Optimized insulin replacement and glucose monitoring underpinned by hypoglycemia-focused structured education should be provided to all with type 1 diabetes complicated by impaired awareness of hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several evidence-based training programs have been developed for this purpose and have been demonstrated to reduce rates of hypoglycemia and improve quality of life among people with type 1 diabetes and impaired hypoglycemia awareness (74,155,156).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [156]
In the citing paper
“Structured education programs, such as Dose Adjustment For Normal Eating (DAFNE) and blood glucose awareness training (BGAT), which provide informed support for active insulin dose self-adjustment, are the key to the prevention of hypoglycemia and lead to sustained falls in level 3 hypoglycemia rates in those at high risk (122,123).”
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Handbook of Psychology and Diabetes
(2013) · Routledge eBooks · doi:10.4324/9781315077369 · Cited by 661
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Pickup, J. C., & Sutton, A. J. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02486.x · Cited by 617
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Cited by
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“Structured education programs, such as Dose Adjustment For Normal Eating (DAFNE) and blood glucose awareness training (BGAT), which provide informed support for active insulin dose self-adjustment, are the key to the prevention of hypoglycemia and lead to sustained falls in level 3 hypoglycemia rates in those at high…”
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
Advances in technology for management of type 1 diabetes
Beck, R. W., Bergenstal, R. M., Laffel, L. M., & Pickup, J. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31142-0 · Cited by 242
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
“In particular, patients with T1DM who develop hypoglycemia unawareness or severe hypoglycemia should receive specialized and professional education to prevent hypoglycemia and restore cognitive abilities in case of hypoglycemia (RCT, Limited) [55].”
BackgroundMcCall, A. L., Lieb, D. C., Gianchandani, R., MacMaster, H., Maynard, G. A., Murad, M. H., Seaquist, E., Wolfsdorf, J. I., Wright, R. F., & Wiercioch, W. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac596 · Cited by 123
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Bosi, E., Choudhary, P., de Valk, H. W., Lablanche, S., Castañeda, J., de Portu, S., Da Silva, J., Ré, R., Vorrink-de Groot, L., Shin, J., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30150-0 · Cited by 125
Self-citationSpeight, J., Choudhary, P., Wilmot, E. G., Hendrieckx, C., Forde, H., Cheung, W. Y., Crabtree, T., Millar, B., Traviss‐Turner, G., Hill, A., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.14944 · Cited by 92
Self-citationEvolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
Is insulin pump therapy effective in Type 1 diabetes?
Pickup, J. C. (2019) · Diabetic Medicine · doi:10.1111/dme.13793 · Cited by 77
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Hering, B. J., Ballou, C. M., Bellin, M. D., Payne, E. H., Kandeel, F., Witkowski, P., Alejandro, R., Rickels, M. R., & Barton, F. B. (2023) · Diabetologia · doi:10.1007/s00125-022-05804-4 · Cited by 51
Hypoglycaemia unawareness in patients with type 1 diabetes
Szadkowska, A., Czyżewska, K., Pietrzak, I., Mianowska, B., Jarosz-Chobot, P. A., & Myśliwiec, M. (2018) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2018.80994 · Cited by 46
Intermittent Use of Continuous Glucose Monitoring: Expanding the Clinical Value of CGM
Ziegler, R., Heinemann, L., Freckmann, G., Schnell, O., Hinzmann, R., & Kulzer, B. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820905577 · Cited by 39
Charleer, S., De Block, C., Nobels, F., Radermecker, R. P., Lowyck, I., Mullens, A., Scarnière, D., Spincemaille, K., Strivay, M., Weber, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1531 · Cited by 39
Lucidi, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1065-6 · Cited by 38
Benhamou, P., Lablanche, S., Vambergue, A., Doron, M., Franc, S., & Charpentier, G. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14214 · Cited by 41
Burckhardt, M., Abraham, M. B., Dart, J., Smith, G. J., Paramalingam, N., O’Dea, J. M., de Bock, M. I., Davis, E. A., & Jones, T. W. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0593 · Cited by 43
“Although some studies assessing the use of diabetes technology in people with IAH showed an improvement in self-reported awareness of hypoglycemia for up to 24 months, 18,36 others did not.”
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Jangam, S. R., Dunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000611 · Cited by 30
Ridder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819871903 · Cited by 32
Flatt, A. J., Little, S. A., Speight, J., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Lubina-Solomon, A., Holmes‐Truscott, E., Chadwick, T. J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0630 · Cited by 32
“Outcomes Twenty-four-week RCT and 24-month outcomeshave previously been reported (8,20).”
BackgroundSelf-citationMartin, C., Criego, A. B., Carlson, A. L., & Bergenstal, R. M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1177-7 · Cited by 34
How has psycho‐behavioural research advanced our understanding of hypoglycaemia in type 1 diabetes?
Hendrieckx, C., Gonder-Frederick, L. A., Heller, S. R., Snoek, F. J., & Speight, J. (2019) · Diabetic Medicine · doi:10.1111/dme.14205 · Cited by 27
Self-citation2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Ko, S. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.4.244 · Cited by 23
Yu, X., Fan, M., Zhao, X., Ding, Y., Liu, X., Yang, S., & Zhang, X. (2023) · Diabetic Medicine · doi:10.1111/dme.15129 · Cited by 24
Siamashvili, M., Davis, H. A., & Davis, S. N. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1979391 · Cited by 28
Nattero‐Chávez, L., Pascual, E. L., de la Villa, E. D. L. C., Cebada, A. B., Ruiz, T., Tobar, A. Q., Lorenzo, M., Sánchez, C., Izquierdo, A., Luque‐Ramírez, M., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110627 · Cited by 19
Speight, J., Holmes‐Truscott, E., Little, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Kerr, D. E., Flanagan, D., Heller, S. R., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0152 · Cited by 20
“It confirms that participants were more satisfied with CSII than MDI, as previously shown with DTSQ, 2,3 and that these improvements were maintained at 2 years.”
InfluentialSelf-citationKłak, A., Mańczak, M., Owoc, J., & Olszewski, R. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16047 · Cited by 41
“We included 7 studies [14,16,20,25-28] in the quantitative synthesis and 4 studies [10,12,29,30] in the qualitative synthesis.”
BackgroundMethodInfluentialPolonsky, W. H., Guzman, S., & Fisher, L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0131 · Cited by 20
McAuley, S. A., Vogrin, S., Lee, M. H., Paldus, B., Trawley, S. L., de Bock, M. I., Abraham, M. B., Bach, L. A., Burt, M. G., Cohen, N. D., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0589 · Cited by 21
“4,24 However, RCTs reporting similar self-treated hypoglycemia among adults using MDIs versus pump may have missed clinically significant hypoglycemia (especially during sleep) when only measuring by reported symptoms and/or SMBG. 8 The HypoCOMPaSS trial observed no difference in time spent in…”
InfluentialSelf-citationNew advances in insulin products
Rajpoot, K., Tekade, M., Sharma, M. C., Molugulu, N., & Tekade, R. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814455-8.00014-1 · Cited by 21
Dewan, N., Shukla, V., Rehni, A. K., Koronowski, K. B., Klingbeil, K. D., Stradecki, H. M., Garrett, T. J., Rundek, T., Pérez‐Pinzón, M. A., & Dave, K. R. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13186 · Cited by 15
β‐Cell and renal transplantation options for diabetes
Flatt, A. J., Bennett, D., Counter, C., Brown, A. L., White, S. A., & Shaw, J. (2019) · Diabetic Medicine · doi:10.1111/dme.14177 · Cited by 16
Self-citationPorcellati, F., Mauro, S. D., Mazzieri, A., Scamporrino, A., Filippello, A., Fano, M. D., Fanelli, C. G., Purrello, F., Malaguarnera, R., & Piro, S. (2021) · Biomolecules · doi:10.3390/biom11091281 · Cited by 19
“Recently, the 2-year follow-up results of this study were published and substantially confirmed those observed at 24 weeks [91].”
ResultPang, J., Zhang, L., Li, X., Sun, F., Qiu, J., Zhao, Y., Wang, J., Liu, L., Wan, X., & Zhang, Y. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02132-w · Cited by 11
“Suitably trained medical staff recommend the use of structured or hypoglycemia-specific education programs and optimization of the treatment plan to prevent and reduce the occurrence of hypoglycemia and FoH [35].”
BackgroundBenhamou, P., Lablanche, S., Vambergue, A., Pou, S., Madrolle, S., Ugalde, H. M. R., Franc, S., & Charpentier, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14654 · Cited by 13
Waldenmaier, D., Freckmann, G., Pleus, S., Hermanns, N., Ehrmann, D., Heinemann, L., & Haug, C. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001848 · Cited by 11
Sepúlveda, E., Jacob, P., Poínhos, R., Carvalho, D. M., Vicente, S., Smith, E. L., Shaw, J., Speight, J., Choudhary, P., de Zoysa, N., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05847-7 · Cited by 12
“001 for all pairwise comparisons; Table 2), reflecting previously published analyses [21, 31, 32].”
BackgroundMethodResultSelf-citationThe impact of diabetes technology advances on quality of life: addressing the barriers to uptake
Kilvert, A., & Fox, C. (2023) · Practical Diabetes · doi:10.1002/pdi.2476 · Cited by 11
Continuous Glucose Monitoring in 2018
Bode, B. W., & Battelino, T. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2502 · Cited by 8
“Impressive and highly clinically relevant results from the HypoDE study are important, and not only because of their obvious face value: in the context of some other similar recent studies—for example, IN CONTROL and HypoCOMPaSS (7)—the German study clearly demonstrates that it takes more than just distributing a CGM…”
Serné, E. H., van den Berg, I. K., Racca, C., van Raalte, D. H., Kramer, M. H. H., de Wit, M., & Snoek, F. J. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0232 · Cited by 6
“11,12 A partly web-based psychoeducational group intervention for people with problematic hypoglycemia called HypoAware, based on key active ingredients of BGAT, resulted in fewer severe hypoglycemic episodes, significantly improved hypoglycemia awareness, and less hypodistress in comparison with…”
Mustonen, J., Rautiainen, P., Lamidi, M., Lavikainen, P., Martikainen, J. A., & Laatikainen, T. K. (2022) · Diabetes Spectrum · doi:10.2337/ds21-0087 · Cited by 7
“In the HypoCompass (Comparison of Optimized MDI Versus Pumps With or Without Sensors in Severe Hypoglycemia) trial (19) and in a trial using the HypoAware intervention (20), the use of rtCGM resulted in a reduction of hypoglycemic episodes and no negative change in A1C levels.”
MethodMaiorino, M. I., Buzzetti, R., Irace, C., Laviola, L., Napoli, N., Pitocco, D., Esposito, K., & on behalf of LIVE CGM working group (2023) · Endocrine · doi:10.1007/s12020-023-03473-w · Cited by 7
Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention
Kahkoska, A. R., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0020 · Cited by 6
“While participants were able to change insulin delivery regimen after the interventionended, theCGMversusSMBGrandomization assignment continued throughout follow-up (20).”
BackgroundInfluentialSathyanarayanan, A., Crabtree, T. S. J., Choudhary, P., Elliott, D., Evans, M. L., Lumb, A. N., & Wilmot, E. G. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109777 · Cited by 4
Self-citationArshad, M. F., Walkinshaw, E., Solomon, A. L., Bernjak, A., Rombach, I., Leelarathna, L., Little, S. A., Evans, M. L., Shaw, J. A. M., Heller, S. R., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15340 · Cited by 4
Self-citationJiménez-Montero, J. G., Solórzano, M. L. C., & Barakat, M. V. (2020) · Diabetes & its Complications · doi:10.33425/2639-9326.1068 · Cited by 3
“In the Hypo Compass [40-41], type 1 diabetes restored hypoglycemia awareness and prevented severe hypoglycemia events without a deterioration of glucose control.”
Loumpardia, P., & Huda, M. S. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88674 · Cited by 3
New technical approach to the diabetes therapy
Dovč, K., & Battelino, T. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05865-x · Cited by 3
Joubert, M., Bouillet, B., Prévost, G., Vermesse, B., Mosnier-Pudar, H., Thébaut, J.-F., Riveline, J., Davoust, N., Guerci, B., & Meyer, L. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.04.002 · Cited by 3
From insulin replacement to bioengineered, encapsulated organoids
Maillard, É., & Sigrist, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102906-0.00015-5 · Cited by 2
Mark‐Wagstaff, C., Deshmukh, H., Wilmot, E. G., Walker, N., Barnes, D., Parfitt, V. J., Saunders, S., Gregory, R., Choudhary, P., Patmore, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15283 · Cited by 3
“17 This could explain the relative youth of those without driving licences in our study, as one possibility is that they may have already been disqualified from driving before starting FSL and so FSL application may have been an intervention designed to enable some of this cohort to reapply for…”
BackgroundSøholm, U., Holmes‐Truscott, E., Broadley, M. M., Amiel, S. A., Hendrieckx, C., Choudhary, P., Pouwer, F., Shaw, J., & Speight, J. (2023) · Diabetic Medicine · doi:10.1111/dme.15231 · Cited by 3
Self-citationRalston, J. D., Anderson, M. L., Ng, J., Bashir, A., Ehrlich, K. J., Burns-Hunt, D., Cotton, M., Hansell, L. D., Hsu, C. W., Hunt, H., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107456 · Cited by 2
Self-citationBashir, A., Flatt, A. J., Richell, G., & Shaw, J. (2024) · Diabetic Medicine · doi:10.1111/dme.15389 · Cited by 2
Self-citationHalliday, J. A., Holmes‐Truscott, E., Thuraisingam, S., Søholm, U., Chatterton, M. L., Russell‐Green, S., Eric, O., Andrikopoulos, S., Black, T., Davidson, S., et al. (2024) · Trials · doi:10.1186/s13063-024-08556-1 · Cited by 2
“Several group-based psycho-educational programmes, involving glucose awareness training, have shown benefits for reducing fear of hypoglycaemia [3, 22–24].”
BackgroundSelf-citationThe effects of a hypoglycaemia education programme on the outcomes in patients with type 2 diabetes
Özen, A. T., & Özcan, Ş. (2024) · Kontakt · doi:10.32725/kont.2024.041 · Cited by 3
Chen, M.-B., Xu, R., Zheng, Q.-H., Zheng, X., Wang, H., Ding, Y., & Yue, M.-X. (2019) · Medicine · doi:10.1097/md.0000000000016850 · Cited by 2
“Owing to insufficient insulin production, patients have to use multiple daily injections (MDIs) of insulin or continuous subcutaneous insulin injection (CSII); otherwise, blood glucose cannot be well controlled.([2]) The incidence of T1DM is much lower than that of T2DM, but T1DM is more dangerous.”
BackgroundO conhecimento de adolescentes com Diabetes Mellitus tipo 1 sobre o seu autocuidado
da Silva, D. P. V., de Morais, R. D. C. M., Pacheco, A. P. F., Campos, L. M., Franzoi, M. A. H., & Silveira, A. O. (2022) · Revista Família Ciclos de Vida e Saúde no Contexto Social · doi:10.18554/refacs.v10i3.5761 · Cited by 2
Messaaoui, A., Tenoutasse, S., Hajselova, L., & Crenier, L. (2023) · Pediatric Diabetes · doi:10.1155/2023/4882902 · Cited by 1
“It has been shown to accurately identify people with T1D with IAH, both in adult [9, 10] and pediatric populations [17, 18].”
Sakane, N., Kato, K., Hata, S., Nishimura, E., Araki, R., Kouyama, K., Hatao, M., Matoba, Y., Matsushita, Y., Domichi, M., et al. (2025) · Diabetology International · doi:10.1007/s13340-025-00846-6 · Cited by 1
“Nevertheless, concerns regarding recurrent SH persist among patients with T1DM despite significant advancements in treatment options such as CGM and continuous subcutaneous insulin infusion (CSII) [12].”
L'insulinothérapie au xxie siècle : une symphonie de plus en plus harmonieuse
Benhamou, P., Hanaire, H. P., & Renard, É. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00179-6 · Cited by 1
Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 Diabetes
Amole, M., WHYTE, L., Ghayee, H. K., Bril, F., Cusi, K. J., & Leey, J. (2021) · Federal Practitioner · doi:10.12788/fp.0156 · Cited by 2
Prise en charge du diabète instable : approche humaine ou technologique ?
Benhamou, P. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30095-6
Hypoglykämien bei Diabetes mellitus: häufig und gefährlich
Holstein, A., & Holstein, D. J. F. (2019) · Diabetes aktuell · doi:10.1055/a-1031-2237
“[26] Little SA, Speight J, Leelarathna L et al.”
Background72/w mit Kollaps nach Schwindel und starkem Schwitzen: Vorbereitung auf die Facharztprüfung: Fall 6
Meyhöfer, S. M. (2021) · Der Internist · doi:10.1007/s00108-021-00944-y
72/w mit Kollaps nach Schwindel und starkem Schwitzen: Vorbereitung auf die Facharztprüfung: Fall 6
Meyhöfer, S. M. (2021) · Der Internist
Treatment of Diabetes — To Pump or Not to Pump
O’Connell, J., Nathan, D. M., O’Brien, T., & O'Keeffe, D. T. (2021) · New England Journal of Medicine · doi:10.1056/nejmclde2112076
Fear of hypoglycemia: a new therapeutic target
Chernaya, M. E., Nersesyan, A. A., Ostroukhova, E. N., & Volkova, A. R. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-4-70-77
New Technologies for Insulin Administration
Forde, H. E., & Choudhary, P. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch33
Traiter les hypoglycémies iatrogènes à l’ère des nouvelles technologies
Monnier, L., & Colette, C. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.02.002
Tadesse, K., Mekonnen, H., Habte, T., Abera, F., Lelago, T., Ayale, M., & Sugebo, F. (2024) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101702
Kong, S.-Y., & Cho, M. (2024) · Healthcare · doi:10.3390/healthcare12141381 · Cited by 3
“However, the use of CGM without specialized training was reportedly ineffective in improving glycemic control or reducing severe hypoglycemia [16], suggesting that healthcare provider interventions, along with specialized training, are critical to ensure the proper use of CGM by patients [17].”
BackgroundImpacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
Sahagún, R. J. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/72390
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch04
Thuraisingam, S., Halliday, J. A., Søholm, U., Holmes‐Truscott, E., Hendrieckx, C., Skinner, T. C., Versace, V. L., & Speight, J. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101513
“Group-based, faceto-face psycho-educational and behavioural training programs focus on improving awareness of, and timely, appropriate responses to, decreasing glucose levels, and have demonstrated benefits in reducing fear of hypoglycaemia [5,8,9].”
Self-citationChujo, D., Imagawa, A., Miura, J., Takahashi, K., Kikuchi, T., Horie, I., Yabe, D., & Shimada, A. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70301
“…trials involving individuals with type 1 diabetes with impaired awareness of hypoglycemia have reported that the use of CSII or CGM could reduce the incidence of severe hypoglycemia compared with treatment with MDI or SMBG 30 ; hence, the effectiveness of these devices could not be dismissed.”
Ralston, J. D., Anderson, M. L., Ng, J., Bashir, A., Ehrlich, K. J., Burns-Hunt, D., Cotton, M., Hansell, L. D., Hsu, C., Hunt, H., et al. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10491-7
Self-citationJancev, M., Serné, E. H., de Valk, H. W., DeVries, J. H., van Sloten, T. T., Snoek, F. J., de Wit, M., & Bosmans, J. E. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100319
(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Metadata
- Authors
- Little, S. A., Speight, J., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Lubina-Solomon, A., Chadwick, T. J., Stocken, D. D., Brennand, C., Marshall, S. M., Wood, R., Kerr, D., Flanagan, D., Heller, S. R., Evans, M. L., & Shaw, J. A. M.
- Affiliations
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Deakin University (AU)
- University of Cambridge (GB)
- University of Sheffield (GB)
- Peninsula College of Medicine and Dentistry (GB)
- Bournemouth University (GB)
- Newcastle University (GB)
- Corresponding author
- Shaw, James A.M.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-04-16
- Volume
- 41
- Issue
- 8
- Pages
- 1600-1607
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2800556369
- Cited by
- 86
- References
- 38
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 12 · 2023: 9 · 2022: 12 · 2021: 16 · 2020: 8 · 2019: 15 · 2018: 5
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Diabetes UK (07/0003556)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, impaired awareness of hypoglycemia, severe hypoglycemia, insulin pump therapy, multiple daily insulin injections, continuous glucose monitoring, self-monitoring of blood glucose, hypoglycemia education, hypoglycemia prevention, HbA1c, treatment satisfaction, fear of hypoglycemia, long-term follow-up
- MeSH terms
- Adult, Awareness, Blood Glucose, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemia, Injections, Insulin, Insulin Infusion Systems, Male, Middle Aged, Severity of Illness Index, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.